Table 3.
Objective responders and gene mutations detected
| Objective response to first-line therapy | First-line everolimus (n = 35) | First-line sunitinib (n = 33) | ||
|---|---|---|---|---|
| n | 1 | 3 | ||
| Histologic subtype | Chromophobe, GA | Papillary, GA | Chromophobe* | Chromophobe |
| Response to first-line therapy (% tumor regression by RECIST) | PR (–58%) | PR (–58%) | PR (–56%) | PR (–56%) |
| Response to second-line therapy | NA | NA | PR with everolimus | SD with everolimus |
| Analysis of mutations | TP53, NFI, PTEN, AXL, MLL2, NOTCH1, SETD2, TSC2, ZRSR | No mutation identified | Not performed | Not performed |
| Objective response to second-line therapy | Second-line sunitinib (n = 21) | Second-line everolimus (n = 23) | ||
|---|---|---|---|---|
| n | 2 | 2 | ||
| Histologic subtype | Translocation carcinoma | Unclassified, GA | Chromophobe* | Papillary |
| Response to second-line therapy (% tumor regression by RECIST) | PR (–38%) | PR (–41%) | PR (–42%) | PR (–34%) |
| Analysis of mutations | Not performed | ATM, CDK6, ERCC4, GLI3 | Not performed | Not performed |
GA = genomic analysis performed; NA = not applicable because patient was still receiving first-line agent; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease.
*
Same patient had PR with sunitinib as first-line therapy and with everolimus as second-line therapy.